COG AAML1031 - Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Objective

This randomized phase III trial studies how well bortezomib and sorafenib tosylate work in treating patients with newly diagnosed acute myeloid leukemia. Bortezomib and sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib and sorafenib tosylate together with combination chemotherapy may be an effective treatment for acute myeloid leukemia.

https://clinicaltrials.gov/ct2/show/NCT01371981?term=aaml1031&rank=1

Location:

Essentia Health Duluth

Disclosures:

None

For more information about a financial conflict of interest (FCOI), review the Essentia Health FCOI policy.

Last Updated: 05/12/2015

Research Study Categories

  • Pediatric Studies

Specialty

  • Cancer
  • Hematology
  • Leukemia
Contact
Cancer Clinical Trials at 218-786-3308